AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Gossamer Bio, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Gossamer Bio director Steven D. Nathan received a stock option grant on June 25, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:

  • Grant of 115,000 stock options to purchase common stock
  • Exercise price set at $1.36 per share
  • Options expire on June 24, 2035
  • Vesting occurs at the earlier of:
    • First anniversary of grant date
    • Next annual stockholder meeting

The award was made under the company's Non-Employee Director Compensation Program. Vesting is contingent on Nathan's continued service on the board of directors through the vesting date. The filing was submitted by attorney-in-fact Jeff Boerneke on June 26, 2025.

Steven D. Nathan, membro del consiglio di amministrazione di Gossamer Bio, ha ricevuto una concessione di stock option il 25 giugno 2025, come riportato in questo modulo Form 4. I dettagli della transazione di titoli derivati includono:

  • Concessione di 115.000 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 1,36 $ per azione
  • Le opzioni scadono il 24 giugno 2035
  • Il vesting avviene al primo verificarsi tra:
    • Il primo anniversario della data di concessione
    • La prossima assemblea annuale degli azionisti

Il premio è stato assegnato nell'ambito del Programma di Compensazione per Direttori Non Dipendenti della società. Il vesting è subordinato alla continuazione del servizio di Nathan nel consiglio di amministrazione fino alla data di maturazione. La documentazione è stata presentata dall'avvocato incaricato Jeff Boerneke il 26 giugno 2025.

Steven D. Nathan, director de Gossamer Bio, recibió una concesión de opciones sobre acciones el 25 de junio de 2025, según se informa en este formulario Form 4. Los detalles de la transacción de valores derivados incluyen:

  • Concesión de 115,000 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $1.36 por acción
  • Las opciones expiran el 24 de junio de 2035
  • La adquisición de derechos ocurre en el primero de los siguientes eventos:
    • Primer aniversario de la fecha de concesión
    • Próxima junta anual de accionistas

El premio se otorgó bajo el Programa de Compensación para Directores No Empleados de la empresa. La adquisición de derechos depende de que Nathan continúe en el consejo de administración hasta la fecha de adquisición. La presentación fue realizada por el apoderado Jeff Boerneke el 26 de junio de 2025.

Gossamer Bio ì´ì‚¬ Steven D. Nathanì€ 2025ë…� 6ì›� 25ì¼ì— 스톡옵션ì� ë¶¶Ä여받았으ë©�, ì´ëŠ” ë³� Form 4 ì œì¶œì„œì— ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�. íŒŒìƒ ì¦ê¶Œ 거래 ì„¸ë¶€ì‚¬í•­ì€ ë‹¤ìŒê³� 같습니다:

  • ì¼ë°˜ ì£¼ì‹ êµ¬ë§¤ë¥� 위한 115,000 ì£¼ì‹ ì˜µì…˜ ë¶¶Äì—�
  • í–‰ì‚¬ê°€ê²©ì€ ì£¼ë‹¹ 1.36달러ë¡� 설정
  • 옵션 만료ì¼ì€ 2035ë…� 6ì›� 24ì�
  • ë² ìŠ¤íŒ…ì€ ë‹¤ìŒ ì¤� 빠른 시ì ì—� ë°œìƒ:
    • ë¶¶Äì—¬ì¼ë¡œë¶€í„� 1ë…� 기ë…ì�
    • ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ

ì� 수ìƒì€ 회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹�. ë² ìŠ¤íŒ…ì€ Nathanì� 베스팅ì¼ê¹Œì§€ ì´ì‚¬íšŒì—ì„� ê³„ì† ê·¼ë¬´í•˜ëŠ” ì¡°ê±´ì—� 달려 있습니다. ì� 제출서는 2025ë…� 6ì›� 26ì� ëŒ€ë¦¬ì¸ Jeff Boernekeì—� ì˜í•´ 제출ë˜ì—ˆìŠµë‹ˆë‹�.

Steven D. Nathan, administrateur de Gossamer Bio, a reçu une attribution d'options d'achat d'actions le 25 juin 2025, comme indiqué dans ce formulaire 4. Les détails de la transaction sur titres dérivés comprennent :

  • Attribution de 115 000 options d'achat pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 1,36 $ par action
  • Les options expirent le 24 juin 2035
  • L'acquisition des droits intervient à la première des dates suivantes :
    • Premier anniversaire de la date d'attribution
    • Prochaine assemblée générale annuelle des actionnaires

Cette attribution a été faite dans le cadre du programme de rémunération des administrateurs non salariés de la société. L'acquisition des droits est conditionnée à la poursuite du mandat de Nathan au conseil d'administration jusqu'à la date d'acquisition. Le dépôt a été effectué par le mandataire Jeff Boerneke le 26 juin 2025.

Steven D. Nathan, Direktor von Gossamer Bio, erhielt am 25. Juni 2025 eine Gewährung von Aktienoptionen, wie in diesem Formular 4 gemeldet wurde. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gewährung von 115.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf 1,36 $ pro Aktie
  • Die Optionen verfallen am 24. Juni 2035
  • Die Vesting erfolgt zum früheren Zeitpunkt von:
    • Erstem Jahrestag des Gewährungsdatums
    • Nächster jährlicher Aktionärsversammlung

Die Zuteilung erfolgte im Rahmen des Vergütungsprogramms für nicht-geschäftsführende Direktoren des Unternehmens. Das Vesting ist abhängig von Nathans fortgesetzter Tätigkeit im Vorstand bis zum Vesting-Datum. Die Einreichung wurde am 26. Juni 2025 vom Bevollmächtigten Jeff Boerneke eingereicht.

Positive
  • None.
Negative
  • None.

Steven D. Nathan, membro del consiglio di amministrazione di Gossamer Bio, ha ricevuto una concessione di stock option il 25 giugno 2025, come riportato in questo modulo Form 4. I dettagli della transazione di titoli derivati includono:

  • Concessione di 115.000 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 1,36 $ per azione
  • Le opzioni scadono il 24 giugno 2035
  • Il vesting avviene al primo verificarsi tra:
    • Il primo anniversario della data di concessione
    • La prossima assemblea annuale degli azionisti

Il premio è stato assegnato nell'ambito del Programma di Compensazione per Direttori Non Dipendenti della società. Il vesting è subordinato alla continuazione del servizio di Nathan nel consiglio di amministrazione fino alla data di maturazione. La documentazione è stata presentata dall'avvocato incaricato Jeff Boerneke il 26 giugno 2025.

Steven D. Nathan, director de Gossamer Bio, recibió una concesión de opciones sobre acciones el 25 de junio de 2025, según se informa en este formulario Form 4. Los detalles de la transacción de valores derivados incluyen:

  • Concesión de 115,000 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio establecido en $1.36 por acción
  • Las opciones expiran el 24 de junio de 2035
  • La adquisición de derechos ocurre en el primero de los siguientes eventos:
    • Primer aniversario de la fecha de concesión
    • Próxima junta anual de accionistas

El premio se otorgó bajo el Programa de Compensación para Directores No Empleados de la empresa. La adquisición de derechos depende de que Nathan continúe en el consejo de administración hasta la fecha de adquisición. La presentación fue realizada por el apoderado Jeff Boerneke el 26 de junio de 2025.

Gossamer Bio ì´ì‚¬ Steven D. Nathanì€ 2025ë…� 6ì›� 25ì¼ì— 스톡옵션ì� ë¶¶Ä여받았으ë©�, ì´ëŠ” ë³� Form 4 ì œì¶œì„œì— ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�. íŒŒìƒ ì¦ê¶Œ 거래 ì„¸ë¶€ì‚¬í•­ì€ ë‹¤ìŒê³� 같습니다:

  • ì¼ë°˜ ì£¼ì‹ êµ¬ë§¤ë¥� 위한 115,000 ì£¼ì‹ ì˜µì…˜ ë¶¶Äì—�
  • í–‰ì‚¬ê°€ê²©ì€ ì£¼ë‹¹ 1.36달러ë¡� 설정
  • 옵션 만료ì¼ì€ 2035ë…� 6ì›� 24ì�
  • ë² ìŠ¤íŒ…ì€ ë‹¤ìŒ ì¤� 빠른 시ì ì—� ë°œìƒ:
    • ë¶¶Äì—¬ì¼ë¡œë¶€í„� 1ë…� 기ë…ì�
    • ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ

ì� 수ìƒì€ 회사ì� 비임ì›� ì´ì‚¬ ë³´ìƒ í”„ë¡œê·¸ëž¨ì—� ë”°ë¼ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹�. ë² ìŠ¤íŒ…ì€ Nathanì� 베스팅ì¼ê¹Œì§€ ì´ì‚¬íšŒì—ì„� ê³„ì† ê·¼ë¬´í•˜ëŠ” ì¡°ê±´ì—� 달려 있습니다. ì� 제출서는 2025ë…� 6ì›� 26ì� ëŒ€ë¦¬ì¸ Jeff Boernekeì—� ì˜í•´ 제출ë˜ì—ˆìŠµë‹ˆë‹�.

Steven D. Nathan, administrateur de Gossamer Bio, a reçu une attribution d'options d'achat d'actions le 25 juin 2025, comme indiqué dans ce formulaire 4. Les détails de la transaction sur titres dérivés comprennent :

  • Attribution de 115 000 options d'achat pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 1,36 $ par action
  • Les options expirent le 24 juin 2035
  • L'acquisition des droits intervient à la première des dates suivantes :
    • Premier anniversaire de la date d'attribution
    • Prochaine assemblée générale annuelle des actionnaires

Cette attribution a été faite dans le cadre du programme de rémunération des administrateurs non salariés de la société. L'acquisition des droits est conditionnée à la poursuite du mandat de Nathan au conseil d'administration jusqu'à la date d'acquisition. Le dépôt a été effectué par le mandataire Jeff Boerneke le 26 juin 2025.

Steven D. Nathan, Direktor von Gossamer Bio, erhielt am 25. Juni 2025 eine Gewährung von Aktienoptionen, wie in diesem Formular 4 gemeldet wurde. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gewährung von 115.000 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis festgelegt auf 1,36 $ pro Aktie
  • Die Optionen verfallen am 24. Juni 2035
  • Die Vesting erfolgt zum früheren Zeitpunkt von:
    • Erstem Jahrestag des Gewährungsdatums
    • Nächster jährlicher Aktionärsversammlung

Die Zuteilung erfolgte im Rahmen des Vergütungsprogramms für nicht-geschäftsführende Direktoren des Unternehmens. Das Vesting ist abhängig von Nathans fortgesetzter Tätigkeit im Vorstand bis zum Vesting-Datum. Die Einreichung wurde am 26. Juni 2025 vom Bevollmächtigten Jeff Boerneke eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nathan Steven D

(Last) (First) (Middle)
3115 MERRYFIELD ROW, SUITE 120

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.36 06/25/2025 A 115,000(1) (2) 06/24/2035 Common Stock 115,000 $0 115,000 D
Explanation of Responses:
1. Award made pursuant to Non-Employee Director Compensation Program.
2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Remarks:
/s/ Jeff Boerneke, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did GOSS director Steven Nathan receive on June 25, 2025?

Steven Nathan received 115,000 stock options with an exercise price of $1.36 per share. These options were granted under the Non-Employee Director Compensation Program and will expire on June 24, 2035.

When do Steven Nathan's GOSS stock options vest?

The stock options will fully vest on the earlier of: (a) the first anniversary of the grant date (June 25, 2026) or (b) GOSS's next annual stockholder meeting, provided Nathan continues serving on the board of directors through the vesting date.

What is the exercise price of GOSS director Steven Nathan's new stock options?

The stock options were granted with an exercise price of $1.36 per share.

How long does Steven Nathan have to exercise his GOSS stock options?

The stock options have a 10-year term and will expire on June 24, 2035.

What is Steven Nathan's role at GOSS according to the Form 4?

According to the Form 4, Steven Nathan serves as a Director of Gossamer Bio, Inc. (GOSS). His address is listed as 3115 Merryfield Row, Suite 120, San Diego, CA 92121.
Gossamer Bio

NASDAQ:GOSS

GOSS Rankings

GOSS Latest News

GOSS Latest SEC Filings

GOSS Stock Data

490.97M
219.32M
3.51%
76.54%
7.97%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO